drugdeliverybusiness7 小时
MannKind reports positive data for inhaled insulin for children
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.
MannKind reports six-month results from Phase 3 INHALE-1 trial
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind ...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial ...
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...